DALLAS, TEXAS — October 25, 2026 — MayMag Biologics, formerly known as Tirzepatide Pharma, today announced a comprehensive expansion of its contract development and manufacturing operations. Operating as a premier Dallas, Texas pharmaceutical manufacturer, MayMag Biologics combines the agility of a 506e outsourcing facility with the comprehensive scale of a cGMP contract manufacturer, delivering high-quality, domestic solutions for complex biologics, peptides, and sterile fill-finish operations.

As demand surges globally for metabolic therapies, complex biologics, and reliable supply chains, MayMag Biologics stands out as a unique, single-source partner serving pharmaceutical developers, healthcare providers, and clinical institutions across North America and worldwide.

End-to-End Capabilities: From API to Finished Auto-Injectors

MayMag Biologics offers an integrated suite of development and commercial manufacturing services across multiple critical therapeutic categories:

GLP-1 & Peptide Excellence: As a specialized peptide API manufacturer, tirzepatide manufacturer, and semaglutide CDMO, MayMag Biologics delivers turn-key development and high-purity production for metabolic and obesity therapies, supported by robust domestic API manufacturer capabilities in the United States.

Sterile Injectables & Delivery Systems: Operating high-throughput aseptic lines, MayMag Biologics is a trusted sterile injectable manufacturer. Its specialized device integrations include serving as an epinephrine auto-injector manufacturer, insulin pen manufacturer, and supplier of advanced delivery platforms for chronic conditions, such as a rheumatoid arthritis autoinjector.

Essential Reagents & Diluents: To ensure complete supply chain continuity for compounding and clinical preparation, the facility acts as a dedicated bacteriostatic water manufacturer and BWFI manufacturer (Bacteriostatic Water for Injection).

Advanced Biologics & Inhalation Therapies: Expanding into next-generation drug products, MayMag Biologics serves as a modern biosimilar CDMO and a specialized inhalation therapeutics manufacturer, facilitating dry powder and liquid formulations for pulmonary applications.

What Makes MayMag Biologics Unique

While conventional contract development and manufacturing organizations (CDMOs) often fragment services between API synthesis, sterile filling, and final packaging, MayMag Biologics offers an end-to-end, domestic operational model that reduces lead times and supply chain vulnerabilities.

Dual-Model Agility (506e Outsourcing + Commercial CDMO): Operating both as a 506e outsourcing facility and a cGMP commercial CDMO, MayMag Biologics rapidly bridges gaps between acute compounding/outsourcing needs and full-scale commercial manufacturing under one roof.

Onshore Supply Chain Resilience: As a U.S.-based Dallas, Texas pharmaceutical manufacturer and domestic API manufacturer, MayMag Biologics mitigates geopolitical supply chain risks, offering domestic security for active pharmaceutical ingredients (APIs) and finished sterile injectables.

Turnkey Device & Fill-Finish Integration: From bulk peptide synthesis to automated primary container filling (vials, cartridges, auto-injectors, and inhalation delivery devices), MayMag Biologics streamlines product delivery under strict cGMP regulatory oversight.

About MayMag Biologics

MayMag Biologics (formerly Tirzepatide Pharma) is a leading U.S.-based cGMP contract manufacturer headquartered in Dallas, Texas. Specializing in sterile injectables, peptide API synthesis, GLP-1 therapeutics, biosimilars, and inhalation products, MayMag Biologics provides end-to-end development, manufacturing, and fill-finish solutions to advance patient health globally.

Media Contact: MayMag Biologics Media Relations Dallas, Texas, USA Website: peptidences.com